T-Therapeutics Ltd company information, Employees & Contact Information

Gyala Therapeutics unveils first-in-class CAR-T therapy targeting CD84 showing strong preclinical efficacy in hard-to-treat leukemias PR Newswire

Tessera Therapeutics Awarded up to $41.3 Million from ARPA-H to Advance In Vivo CAR-T Therapies GlobeNewswire

ViroCell and AvenCell to advance allogeneic CAR-T therapy manufacture Pharmaceutical Technology

ViroCell Biologics and AvenCell Therapeutics Announce Retroviral Vector Manufacturing Collaboration to Accelerate Development of Novel Allogeneic CAR-T Therapies for Blood Cancers Business Wire

Enabling next-generation engineered TCR-T therapies based on high-throughput TCR discovery from diagnostic tumor biopsies Nature

ViroCell Biologics and AvenCell Therapeutics partner to accelerate allogeneic CAR-T therapy development Pharmafile

Affini-T Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference Business Wire

Marker Therapeutics to Spotlight Multi-Antigen Recognizing GlobeNewswire

T-Therapeutics Series A Raises $59M for Development of TCR Cancer Therapies Inside Precision Medicine

Affini-T Therapeutics to Present Trial-in-Progress Poster and Preclinical Data from Its Oncogenic Driver Programs Targeting TP53 R175H, KRAS G12D and KRAS-G12V at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting Yahoo Finance

FDA clears IND for Verismo Therapeutics’ CAR-T therapy Clinical Trials Arena

Press Release Service: Affini-T Therapeutics Presents Preclinical Data from its Oncogenic Driver Programs Targeting KRAS G12D and p53 R175H at the American Association for Cancer Research (AACR) Annual Meeting 2024 CRISPR Medicine News

Fate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 Congress GlobeNewswire

Capstan Therapeutics Announces Initiation of Phase 1 Trial of Lead In Vivo CAR-T Therapy, CPTX2309, for Treating Autoimmune Disease Business Wire

CAR-T cell therapy for cancer: current challenges and future directions Nature

Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting PR Newswire

Making drugs from T cells: The quantitative pharmacology of engineered T cell therapeutics Nature

CAR T therapy beyond cancer: the evolution of a living drug Nature

PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: a phase 1 trial Nature

CAR-T therapy dilemma and innovative design strategies for next generation Nature

Affini-T Therapeutics shutting down Seattle lab GeekWire

Poseida Therapeutics Presents New Case Study Demonstrating Reactivation of CAR-T Therapy with a T-Cell Engager in a Patient with Relapsed Multiple Myeloma PR Newswire

Cytokine-mediated CAR T therapy resistance in AML Nature

Allogene Therapeutics Launches CAR T Together™, a First-of-its-Kind Initiative with Leading Oncologists Nationwide, Focused on Accelerating Development and Clinical Trial Recruitment for “Off-The-Shelf” Allogeneic Cell Therapy Investigational Products Allogene

Affini-T Therapeutics Appoints Industry Veteran Thaminda Ramanayake, M.S., MBA, as Chief Business Officer Business Wire

Long-term outcomes following CAR T cell therapy: what we know so far Nature

Watkins Advises Affini-T Therapeutics, Inc. in Its US$175 Million Financing Latham & Watkins LLP

T-knife Therapeutics Announces Five Presentations at GlobeNewswire

Cartesian Therapeutics Doses First Patient With mRNA CAR-T Descartes-15 in Trial for R/R Multiple Myeloma CGTLive®

CAR-T therapy for multiple sclerosis enters US trials for first time Nature

Poseida Therapeutics Reports Positive Interim Phase 1 Results for Allogeneic CAR-T Therapy P-BCMA-ALLO1 with High Overall Response Rates in Heavily Pretreated Relapsed/Refractory Multiple Myeloma Patients PR Newswire

Press Release Service: Affini-T Therapeutics to Present Novel CRISPR Gene Editing Data from its Oncogenic Driver Program Targeting KRAS at the American Society of Gene and Cell Therapy 26th Annual Meeting CRISPR Medicine News

AbbVie to buy CAR-T developer Capstan in deal worth up to $2.1B BioPharma Dive

Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More PharmTech

F.D.A. Issues Warning of Cancer Risk Linked to CAR-T Therapies (Published 2024) The New York Times

Fate Therapeutics’ iPSC-derived CAR-T FT819 Nabs FDA RMAT Designation for Lupus CGTLive®

Cartesian Therapeutics’ mRNA CAR-T Descartes-08 Continues to Show Efficacy in Phase 2b Myasthenia Gravis Trial CGTLive®

T-knife Therapeutics Presents Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting Demonstrating a Potential Best-in-Class PRAME Targeted TCR-T Therapy GlobeNewswire

Fred Hutch spinout Affini-T Therapeutics lands $175M for cell therapies to treat solid tumors GeekWire

CAR-T biotech Cargo Therapeutics prices $281M IPO BioPharma Dive

Optimizing the manufacturing and antitumour response of CAR T therapy Nature

Affini-T Therapeutics Completes $175 Million Financing Co-Led by Vida Ventures and Leaps by Bayer to Advance Groundbreaking T Cell Therapies for Solid Tumor Patients with Oncogenic Driver Mutations Business Wire

CAR-T Therapy Descartes-08 Demonstrates Efficacy, Safety in Phase 2 Trial of Myasthenia Gravis NeurologyLive

CAR-T cell therapy: current limitations and potential strategies - Blood Cancer Journal Nature

Affini-T Therapeutics Appoints Pioneering T Cell Therapy and KRAS Developer Dirk Nagorsen, M.D., as Chief Medical Officer Business Wire

Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma Nature

Cartesian Therapeutics’ Myasthenia Gravis mRNA CAR-T Descartes-08 Garners FDA RMAT Designation CGTLive®

Harnessing the power of cell therapy AstraZeneca

Two Mass. biotech startups undergo restructuring as industry funding wanes The Business Journals

Roche inks $1.5B Poseida buyout, betting off-the-shelf CAR-Ts will democratize access to cell therapies Fierce Biotech

AbbVie Plunks Down $2.1B for Capstan and Its Novel CAR T Therapies BioSpace

Upsized Kyverna IPO Gets $319M to Bring CAR T-Therapy to Autoimmune Diseases MedCity News

‘How do you decide?’: Cancer treatment’s CAR-T crisis has patients dying on a waitlist statnews.com

Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases GlobeNewswire

NKure - CRISPR Therapeutics partner to develop off-the-shelf CAR-T therapy BusinessLine

Cartogene Therapeutics to bring CAR-T therapies to India-Establishes a facility with 700+patient annual capacity in Gurugram VCCircle

Sloan Kettering and Juno Therapeutics win over $1.1 billion after jury verdict and post-trial motions in patent dispute with Kite Pharma/Gilead involving CAR-T therapy Jones Day